Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Dispositivo médico para tratamientos no invasivos de dolor crónico neuropático y oncológico

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOIT20170511001
Publicado:
29/05/2017
Caducidad:
29/05/2018
Resumen:
Una empresa italiana ha desarrollado un tratamiento no invasivo basado en un nuevo dispositivo médico para el tratamiento del dolor crónico neuropático y oncológico resistente a opiáceos y otros tipos de tratamientos. Esta terapia evita efectos secundarios nocivos, potencialmente mortales y graves. Se trata de un dispositivo médico autónomo de electroanalgesia que no necesita combinarse con otras terapias analgésicas y que se emplea principalmente en atención ambulatoria, hospitales y centros de cuidados paliativos. La empresa busca socios con el fin de establecer acuerdos de joint venture y comercialización con asistencia técnica.

Details

Tittle:
Medical device for non-invasive treatments of chronic neuropathic and oncologic pain
Summary:
An Italian company has developed a non-invasive treatment based on an innovative medical device for chronic neuropathic and oncologic pain resistant to opiates and other types of treatment.The therapy avoids the harmful, potentially fatal, adverse side effects.The technology is a stand-alone medical ectroanalgesia device that does not require combinations with other analgesic therapies. The company is interested in joint venture and/or commercial agreement with technical cooperation.
Description:
The Italian company is a bioengineering research centre that has developed a non-invasive electro-analgesia therapy based on a new generation of medical device.
The device is based on 5 artificial neurons which were developed to non-invasively transmit information recognizable as "self" and "non pain" to the central nervous system (CNS). A proprietary algorithm dynamically generates specific strings of "no pain" information, in order to achieve the goal of immediate and complete analgesia, re-modulation of the pain system, a high level of safety and long-term efficacy. It has unique characteristics made by a software and a hardware module OEM (original equipment manufacturer) dedicated for this aim.
The tool has a trade market authorization in Europe (CE 0476) and in the US - FDA 510(k) - Section 510(k) of the Food, Drug and Cosmetic Act. Other countries can directly convert these authorization locally.

The medical device is a very effective, non-invasive and mainly to be used in ambulatory care, hospital facilities, Hospice. If carried out correctly the analgesic effect during the treatment is very rapid. In just a couple of seconds the pain perception completely disappears. This is true even in cases where pain is of high intensity and non responsive or poorly responsive to opioids or other electro-analgesia devices such as TENS (TransCutaneous Electrical Nerve Stimulation ) or implanted devices.

Clinical trials have been carried out on patients suffering of severe pain, untreatable resistant to opioids and other therapies, including implanted devices and surgical therapies. if correctly used it is a control tool for severe chronic neuropathic pain, Intractable Cancer Pain, Chemotherapy-Induced Peripheral Neuropathy (CIPN), Failed Back Surgery Syndrome, Sciatic and - Lumbar Pain, Post-Herpetic Neuralgia (PHN - HVZ), Post-Surgical Pain, Brachial Plexus Pain, Low Back Pain (LBP).
Its usage is supported in prestigious Universities and Research Centres in the US, Europe and Asia

The company is looking for foreign partners active in medical sector interested in creating a new entity (joint venture) to achieve different goals: business expansion moving into new overseas markets; exploration of other variants of the Italian technology (e.g. a Military version for field hospitals and mobile clinics); development of new patents. The Italian company will be provided with forms of commercial and support control, ensuring compliance with key points regarding quality of care, scientific aspects and / or technological development.
The company is also interested in Commercial agreement with technical assistance. The Italian company will maintain the patent paternity, but grants the rights of exploitation, providing all necessary support to industrial production, clinical technology management, and any its developments.

Advantages and Innovations:
The non-invasive electro-analgesia therapy, developed by the Italian company, is based on a new generation of medical device using 5 artificial neurons and an autonomous theoretical model (it has a U.S. FDA 510(k)-cleared and European CE mark-certified).
It is the only therapy that according to official clinical trials and normal hospital use is highly effective in chronic neuropathic and cancer pain, previously considered untreatable, or poorly responsive to strong drugs mix - even in cases where opioids and other treatments fail.
At the current state of knowledge, the treatment apart from not producing undesired effects, it is also more economically convenient compared to other solutions and produces better results in patients
The device´s active principle is such that synthetic "non-pain" information is transmitted by C fibers surface receptors. Therefore, the traditional electric stimulation of A-Beta fibers to produce paraesthesia and/or block the conduction of nerve fibers to produce an analgesic effect, ie, via TENS machines (TransCutaneous Electrical Nerve Stimulation) is abandoned. The goal of the Italian company device is to eliminate pain during treatment, and allow for long lasting good analgesia after a cycle of 10 to 12 consecutive treatments performed over a period of two weeks.
Stage of Development:
Already on the market
IPs:
Patents granted,Trade Marks

Partner sought

Type and Role of Partner Sought:
The company is interested in Joint venture agreements and commercial agreements with technical assistance.

With regards to Joint venture, the partner sought should be active in medical field and with specific expertise and know-how in therapeutic medical devices or in similar markets/segments. The partner should have established distribution channels in its own market, specialised staff, technical expertise and financial resources to broaden the current offering of a single medical device with a portable version fit for critical scenarios (typically military camp hospitals), mobile clinics, home-care.
About Commercial agreement with technical assistance, the Italian company is looking for a partner interested to the acquisition of the technology with commercial purpose. The Italian company will maintain the patent paternity, but grants the rights of exploitation, providing all necessary support to industrial production, clinical technology management, and any its developments.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Italian

Keywords

Technology Keywords:
06001012 Investigaciones médicas
06001 Medicina, salud humana
06001013 Tecnología médica / ingeniería biomédica